Intrinsic value of GW Pharmaceuticals ADR - GWPH

Previous Close

$146.22

  Intrinsic Value

$0.31

stock screener

  Rating & Target

str. sell

-100%

Previous close

$146.22

 
Intrinsic value

$0.31

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of GWPH stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2017(a)
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -23.08
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  10
  11
  11
  12
  12
  12
  13
  13
  14
  14
  15
  15
  16
  17
  17
  18
  19
  20
  21
  22
  23
  24
  25
  26
  27
  29
  30
  31
  33
  34
  36
Variable operating expenses, $m
 
  133
  136
  140
  143
  148
  153
  158
  163
  169
  176
  182
  189
  197
  205
  214
  224
  234
  244
  255
  267
  279
  292
  306
  321
  336
  352
  369
  387
  406
  425
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  196
  133
  136
  140
  143
  148
  153
  158
  163
  169
  176
  182
  189
  197
  205
  214
  224
  234
  244
  255
  267
  279
  292
  306
  321
  336
  352
  369
  387
  406
  425
Operating income, $m
  -186
  -122
  -125
  -128
  -131
  -135
  -140
  -144
  -149
  -155
  -161
  -166
  -173
  -180
  -188
  -196
  -205
  -214
  -223
  -234
  -244
  -256
  -268
  -280
  -293
  -307
  -322
  -338
  -354
  -371
  -389
EBITDA, $m
  -180
  -115
  -117
  -120
  -124
  -127
  -132
  -136
  -141
  -146
  -152
  -158
  -164
  -171
  -178
  -186
  -194
  -203
  -212
  -221
  -232
  -242
  -254
  -266
  -278
  -291
  -305
  -320
  -335
  -352
  -369
Interest expense (income), $m
  1
  1
  1
  1
  2
  2
  2
  3
  3
  4
  4
  5
  5
  6
  7
  7
  8
  9
  10
  11
  12
  12
  14
  15
  16
  17
  18
  20
  21
  23
  24
Earnings before tax, $m
  -185
  -123
  -126
  -129
  -133
  -137
  -142
  -147
  -153
  -159
  -165
  -171
  -178
  -186
  -195
  -203
  -213
  -223
  -233
  -244
  -256
  -268
  -281
  -295
  -309
  -324
  -341
  -357
  -375
  -394
  -413
Tax expense, $m
  -25
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -160
  -123
  -126
  -129
  -133
  -137
  -142
  -147
  -153
  -159
  -165
  -171
  -178
  -186
  -195
  -203
  -213
  -223
  -233
  -244
  -256
  -268
  -281
  -295
  -309
  -324
  -341
  -357
  -375
  -394
  -413

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  293
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  405
  175
  179
  184
  189
  195
  201
  208
  215
  223
  232
  241
  251
  261
  272
  284
  297
  310
  324
  338
  354
  370
  388
  406
  425
  445
  467
  489
  513
  538
  564
Adjusted assets (=assets-cash), $m
  112
  175
  179
  184
  189
  195
  201
  208
  215
  223
  232
  241
  251
  261
  272
  284
  297
  310
  324
  338
  354
  370
  388
  406
  425
  445
  467
  489
  513
  538
  564
Revenue / Adjusted assets
  0.089
  0.063
  0.061
  0.065
  0.063
  0.062
  0.065
  0.063
  0.065
  0.063
  0.065
  0.062
  0.064
  0.065
  0.063
  0.063
  0.064
  0.065
  0.065
  0.065
  0.065
  0.065
  0.064
  0.064
  0.064
  0.065
  0.064
  0.063
  0.064
  0.063
  0.064
Average production assets, $m
  25
  63
  65
  66
  68
  70
  73
  75
  78
  81
  84
  87
  91
  94
  98
  103
  107
  112
  117
  122
  128
  134
  140
  147
  154
  161
  169
  177
  185
  194
  204
Working capital, $m
  292
  -52
  -53
  -54
  -56
  -58
  -60
  -62
  -64
  -66
  -69
  -71
  -74
  -77
  -81
  -84
  -88
  -92
  -96
  -100
  -105
  -110
  -115
  -120
  -126
  -132
  -138
  -145
  -152
  -159
  -167
Total debt, $m
  6
  7
  9
  11
  13
  16
  18
  21
  24
  28
  31
  35
  39
  44
  49
  54
  59
  64
  70
  77
  83
  90
  98
  105
  114
  122
  131
  141
  151
  161
  172
Total liabilities, $m
  67
  75
  76
  78
  80
  83
  85
  88
  92
  95
  99
  102
  107
  111
  116
  121
  126
  132
  138
  144
  150
  157
  165
  173
  181
  189
  198
  208
  218
  229
  240
Total equity, $m
  338
  101
  103
  106
  109
  112
  116
  120
  124
  128
  133
  139
  144
  150
  157
  163
  171
  178
  186
  195
  204
  213
  223
  233
  245
  256
  268
  281
  295
  309
  324
Total liabilities and equity, $m
  405
  176
  179
  184
  189
  195
  201
  208
  216
  223
  232
  241
  251
  261
  273
  284
  297
  310
  324
  339
  354
  370
  388
  406
  426
  445
  466
  489
  513
  538
  564
Debt-to-equity ratio
  0.018
  0.070
  0.090
  0.100
  0.120
  0.140
  0.160
  0.180
  0.200
  0.220
  0.240
  0.250
  0.270
  0.290
  0.310
  0.330
  0.350
  0.360
  0.380
  0.390
  0.410
  0.420
  0.440
  0.450
  0.460
  0.480
  0.490
  0.500
  0.510
  0.520
  0.530
Adjusted equity ratio
  0.402
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575
  0.575

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -160
  -123
  -126
  -129
  -133
  -137
  -142
  -147
  -153
  -159
  -165
  -171
  -178
  -186
  -195
  -203
  -213
  -223
  -233
  -244
  -256
  -268
  -281
  -295
  -309
  -324
  -341
  -357
  -375
  -394
  -413
Depreciation, amort., depletion, $m
  6
  7
  7
  7
  8
  8
  8
  8
  9
  9
  9
  9
  9
  9
  10
  10
  11
  11
  12
  12
  13
  13
  14
  15
  15
  16
  17
  18
  19
  19
  20
Funds from operations, $m
  -110
  -116
  -118
  -122
  -125
  -129
  -134
  -139
  -144
  -150
  -156
  -162
  -169
  -177
  -185
  -193
  -202
  -211
  -221
  -232
  -243
  -255
  -267
  -280
  -294
  -308
  -324
  -340
  -357
  -374
  -393
Change in working capital, $m
  24
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -7
  -8
Cash from operations, $m
  -134
  -115
  -117
  -120
  -124
  -128
  -132
  -137
  -142
  -147
  -153
  -160
  -167
  -174
  -181
  -190
  -198
  -208
  -217
  -228
  -238
  -250
  -262
  -275
  -288
  -302
  -317
  -333
  -350
  -367
  -385
Maintenance CAPEX, $m
  0
  -6
  -6
  -6
  -7
  -7
  -7
  -7
  -8
  -8
  -8
  -8
  -9
  -9
  -9
  -10
  -10
  -11
  -11
  -12
  -12
  -13
  -13
  -14
  -15
  -15
  -16
  -17
  -18
  -19
  -19
New CAPEX, $m
  -20
  0
  -1
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -9
  -9
  -9
Cash from investing activities, $m
  -19
  -6
  -7
  -8
  -9
  -9
  -9
  -9
  -11
  -11
  -11
  -11
  -13
  -13
  -13
  -14
  -15
  -16
  -16
  -17
  -18
  -19
  -19
  -21
  -22
  -22
  -24
  -25
  -27
  -28
  -28
Free cash flow, $m
  -153
  -121
  -125
  -128
  -132
  -137
  -141
  -147
  -152
  -158
  -165
  -171
  -179
  -187
  -195
  -204
  -213
  -223
  -234
  -245
  -256
  -269
  -282
  -295
  -310
  -325
  -341
  -358
  -376
  -394
  -414
Issuance/(repayment) of debt, $m
  -1
  1
  2
  2
  2
  2
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  6
  6
  6
  7
  7
  7
  8
  8
  9
  9
  10
  10
  11
  11
Issuance/(repurchase) of shares, $m
  0
  124
  128
  132
  136
  141
  146
  151
  157
  163
  170
  176
  184
  192
  201
  210
  220
  230
  241
  253
  265
  278
  291
  305
  320
  336
  353
  370
  389
  408
  428
Cash from financing (excl. dividends), $m  
  -2
  125
  130
  134
  138
  143
  149
  154
  160
  166
  174
  180
  188
  196
  206
  215
  225
  236
  247
  259
  272
  285
  298
  313
  328
  345
  362
  380
  399
  419
  439
Total cash flow (excl. dividends), $m
  -162
  4
  5
  5
  6
  6
  7
  7
  8
  9
  9
  9
  10
  10
  11
  11
  12
  13
  14
  14
  15
  16
  17
  18
  19
  20
  21
  22
  23
  24
  25
Retained Cash Flow (-), $m
  146
  -124
  -128
  -132
  -136
  -141
  -146
  -151
  -157
  -163
  -170
  -176
  -184
  -192
  -201
  -210
  -220
  -230
  -241
  -253
  -265
  -278
  -291
  -305
  -320
  -336
  -353
  -370
  -389
  -408
  -428
Prev. year cash balance distribution, $m
 
  276
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  3
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  8
  8
  9
Cash available for distribution, $m
 
  156
  -123
  -126
  -130
  -134
  -139
  -144
  -149
  -155
  -161
  -168
  -175
  -182
  -190
  -199
  -208
  -217
  -228
  -238
  -250
  -262
  -274
  -288
  -302
  -316
  -332
  -348
  -366
  -384
  -403
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  149
  -113
  -110
  -107
  -104
  -101
  -97
  -93
  -89
  -84
  -80
  -75
  -69
  -64
  -58
  -53
  -47
  -42
  -37
  -32
  -27
  -23
  -19
  -15
  -12
  -10
  -7
  -6
  -4
  -3
Current shareholders' claim on cash, %
  100
  88.9
  78.9
  70.0
  62.0
  54.9
  48.6
  43.0
  38.0
  33.6
  29.6
  26.2
  23.1
  20.4
  18.0
  15.9
  14.0
  12.3
  10.8
  9.6
  8.4
  7.4
  6.5
  5.7
  5.0
  4.4
  3.9
  3.4
  3.0
  2.6
  2.3

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

FINANCIAL RATIOS  of  GW Pharmaceuticals ADR (GWPH)

Valuation Ratios
P/E Ratio -276.4
Price to Sales 4422.6
Price to Book 130.8
Price to Tangible Book
Price to Cash Flow -330
Price to Free Cash Flow -287.2
Growth Rates
Sales Growth Rate -23.1%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 81.8%
Cap. Spend. - 3 Yr. Gr. Rate 17.3%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 1.8%
Total Debt to Equity 1.8%
Interest Coverage -184
Management Effectiveness
Return On Assets -33.3%
Ret/ On Assets - 3 Yr. Avg. -22.9%
Return On Total Capital -38.4%
Ret/ On T. Cap. - 3 Yr. Avg. -26.6%
Return On Equity -38.9%
Return On Equity - 3 Yr. Avg. -26.9%
Asset Turnover 0
Profitability Ratios
Gross Margin 60%
Gross Margin - 3 Yr. Avg. 73.6%
EBITDA Margin -1780%
EBITDA Margin - 3 Yr. Avg. -915.2%
Operating Margin -1860%
Oper. Margin - 3 Yr. Avg. -954.9%
Pre-Tax Margin -1850%
Pre-Tax Margin - 3 Yr. Avg. -951.6%
Net Profit Margin -1600%
Net Profit Margin - 3 Yr. Avg. -782.2%
Effective Tax Rate 13.5%
Eff/ Tax Rate - 3 Yr. Avg. 20.6%
Payout Ratio 0%

GWPH stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the GWPH stock intrinsic value calculation we used $11 million for the last fiscal year's total revenue generated by GW Pharmaceuticals ADR. The default revenue input number comes from 2017 income statement of GW Pharmaceuticals ADR. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our GWPH stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for GWPH is calculated based on our internal credit rating of GW Pharmaceuticals ADR, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of GW Pharmaceuticals ADR.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of GWPH stock the variable cost ratio is equal to 1185.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for GWPH stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 15% for GW Pharmaceuticals ADR.

Corporate tax rate of 27% is the nominal tax rate for GW Pharmaceuticals ADR. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the GWPH stock is equal to 25%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for GWPH are equal to 564.6%.

Life of production assets of 10 years is the average useful life of capital assets used in GW Pharmaceuticals ADR operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for GWPH is equal to -462.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $376 million for GW Pharmaceuticals ADR - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 302 million for GW Pharmaceuticals ADR is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of GW Pharmaceuticals ADR at the current share price and the inputted number of shares is $44.2 billion.

RELATED COMPANIES Price Int.Val. Rating
NVS Novartis ADR 82.27 59.65  sell
INSY Insys Therapeu 7.83 1.29  str.sell
ZGNX Zogenix 58.40 5.88  str.sell
FLKS Flex Pharma 0.880 0.43  str.sell
GSK GlaxoSmithKlin 41.87 39.73  hold

COMPANY NEWS

▶ Is Marijuana the Best Medicine for Epilepsy?   [Jul-19-18 04:10PM  Motley Fool]
▶ 5 Big Biotech Stories to Watch   [03:07PM  TheStreet.com]
▶ Why Zogenix Inc. Shares Jumped 10% on Friday   [Jul-13-18 05:34PM  Motley Fool]
▶ The Best Marijuana Stocks in the Second Quarter   [Jul-04-18 09:21AM  Motley Fool]
▶ The FDA Finally Weighs In on Marijuana, and It's a Go   [Jun-30-18 02:00PM  Motley Fool]
▶ 6 Marijuana Stocks to Invest In for 1,000%+ Gains   [Jun-28-18 07:18AM  InvestorPlace]
▶ US Approves First Cannabis-Based Drug   [04:15AM  Investopedia]
▶ FDA approves marijuana drug   [05:08PM  Yahoo Finance Video]
▶ [$$] FDA Approves First Drug Derived From Marijuana Plant   [04:14PM  The Wall Street Journal]
▶ Could This State Be the Next to Legalize Marijuana?   [Jun-24-18 07:21AM  Motley Fool]
▶ Some fear changes to state laws as US weighs pot medicine   [Jun-19-18 02:42PM  Associated Press]
▶ 7 Reasons Marijuana Won't Be Legalized in the U.S.   [Jun-17-18 04:48PM  Motley Fool]
▶ Why Marijuana Stock GW Pharmaceuticals Gained 21% in May   [Jun-14-18 11:59AM  Motley Fool]
▶ Forget Canada! This Marijuana Vote Is Far More Important   [Jun-10-18 11:41AM  Motley Fool]
▶ 3 Biotechs With Huge FDA Decisions in June   [May-31-18 06:31AM  Motley Fool]
▶ Most-Shorted Marijuana Stocks   [May-29-18 08:10AM  Investopedia]
▶ Rescheduling Marijuana in the U.S. Could Backfire   [May-27-18 07:23AM  Motley Fool]
▶ 5 Marijuana Stocks To Watch In 2018   [May-20-18 07:30PM  Oilprice.com]
Financial statements of GWPH
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.